Benjamin MordmÃ¼ller

List of Publications by Year
in descending order

191 papers	10,546 citations	41344 49 h-index	40979 93 g-index

201 all docs	201 docs citations	201 times ranked	10746 citing authors

#	Article	IF	Citations
1	An efficient singleâ€cell based method for linking human T cell phenotype to T cell receptor sequence and specificity. European Journal of Immunology, 2022, 52, 237-246.	2.9	3
2	Transcriptional correlates of malaria in RTS,S/AS01-vaccinated African children: a matched caseâ€“control study. ELife, 2022, 11, .	6.0	4
3	Strong off-target antibody reactivity to malarial antigens induced by RTS,S/AS01E vaccination is associated with protection. JCI Insight, 2022, 7, .	5.0	6
4	Efficacy, T cell activation and antibody responses in accelerated Plasmodium falciparum sporozoite chemoprophylaxis vaccine regimens. Npj Vaccines, 2022, 7, .	6.0	3
5	Assessment of malaria transmission intensity and insecticide resistance mechanisms in three rural areas of the Moyen OgoouÃ© Province of Gabon. Parasites and Vectors, 2022, 15, .	2.5	5
6	Clonal evolution and TCR specificity of the human T _{FH} cell response to Plasmodium falciparum CSP. Science Immunology, 2022, 7, .	11.9	5
7	Cellular and antibody response in GMZ2-vaccinated Gabonese volunteers in a controlled human malaria infection trial. Malaria Journal, 2022, 21, .	2.3	3
8	Plasmodium falciparum 7G8 challenge provides conservative prediction of efficacy of PfNF54-based PfSPZ Vaccine in Africa. Nature Communications, 2022, 13, .	12.8	8
9	In vitro activity of eravacycline, a novel synthetic halogenated tetracycline, against the malaria parasite Plasmodium falciparum. Journal of Global Antimicrobial Resistance, 2021, 24, 93-97.	2.2	8
10	Molecular Epidemiology of Mansonella Species in Gabon. Journal of Infectious Diseases, 2021, 223, 287-296.	4.0	18
11	Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity. Nature Communications, 2021, 12, 324.	12.8	79
12	Development of sustainable research excellence with a global perspective on infectious diseases: Centre de Recherches MÃ©dicales de LambarÃ©nÃ© (CERMEL), Gabon. Wiener Klinische Wochenschrift, 2021, 133, 500-508.	1.9	14
13	Genetic Diversity of Enteric Viruses in Children under Five Years Old in Gabon. Viruses, 2021, 13, 545.	3.3	6
14	3-Hydroxy-propanamidines, a New Class of Orally Active Antimalarials Targeting Plasmodium falciparum. Journal of Medicinal Chemistry, 2021, 64, 3035-3047.	6.4	5
15	Expansion of Functional Myeloid-Derived Suppressor Cells in Controlled Human Malaria Infection. Frontiers in Immunology, 2021, 12, 625712.	4.8	10
16	Molecular epidemiology of respiratory syncytial virus in children in subâ€Saharan Africa. Tropical Medicine and International Health, 2021, 26, 810-822.	2.3	6
17	Systems analysis and controlled malaria infection in Europeans and Africans elucidate naturally acquired immunity. Nature Immunology, 2021, 22, 654-665.	14.5	24
18	Heterologous protection against malaria by a simple chemoattenuated PfSPZ vaccine regimen in a randomized trial. Nature Communications, 2021, 12, 2518.	12.8	34

#	Article	IF	Citations
19	A call to caution when hydroxychloroquine is given to elderly patients with COVID-19. International Journal of Infectious Diseases, 2021, 106, 265-268.	3.3	1
20	Exploratory analysis of the effect of helminth infection on the immunogenicity and efficacy of the asexual blood-stage malaria vaccine candidate GMZ2. PLoS Neglected Tropical Diseases, 2021, 15, e0009361.	3.0	13
21	Extended follow-up of children in a phase2b trial of the GMZ2 malaria vaccine. Vaccine, 2021, 39, 4314-4319.	3.8	10
22	Prevalence of Pathogens in Young Children Presenting to Hospital with Diarrhea from LambarÃ©nÃ©, Gabon. American Journal of Tropical Medicine and Hygiene, 2021, 105, 254-260.	1.4	4
23	Afucosylated Plasmodium falciparum-specific IgG is induced by infection but not by subunit vaccination. Nature Communications, 2021, 12, 5838.	12.8	36
24	Immunosuppression in Malaria: Do Plasmodium falciparum Parasites Hijack the Host?. Pathogens, 2021, 10, 1277.	2.8	17
25	Molecular surveillance and genetic divergence of rotavirus A antigenic epitopes in Gabonese children with acute gastroenteritis. EBioMedicine, 2021, 73, 103648.	6.1	6
26	PAD4 controls chemoattractant production and neutrophil trafficking in malaria. Journal of Leukocyte Biology, 2021, , .	3.3	4
27	Boromycin has Rapid-Onset Antibiotic Activity Against Asexual and Sexual Blood Stages of Plasmodium falciparum. Frontiers in Cellular and Infection Microbiology, 2021, 11, 802294.	3.9	4
28	Growth Rate of Plasmodium falciparum: Analysis of Parasite Growth Data from Malaria Volunteer Infection Studies. Journal of Infectious Diseases, 2020, 221, 963-972.	4.0	15
29	Ivermectin for causal malaria prophylaxis: a randomised controlled human infection trial. Tropical Medicine and International Health, 2020, 25, 380-386.	2.3	15
30	Regional Variation of Extended-Spectrum Beta-Lactamase (ESBL)-Producing Enterobacterales, Fluoroquinolone-Resistant Salmonella enterica and Methicillin-Resistant Staphylococcus aureus Among Febrile Patients in Sub-Saharan Africa. Frontiers in Microbiology, 2020, 11, 567235.	3.5	13
31	Test and treat COVID 65 plus - Hydroxychloroquine versus placebo in early ambulatory diagnosis and treatment of older patients with COVID19: A structured summary of a study protocol for a randomised controlled trial. Trials, 2020, 21, 635.	1.6	5
32	Impact of Helminth Infections during Pregnancy on Vaccine Immunogenicity in Gabonese Infants. Vaccines, 2020, 8, 381.	4.4	8
33	Antigen-stimulated PBMC transcriptional protective signatures for malaria immunization. Science Translational Medicine, 2020, 12, .	12.4	33
34	Effect of immune regulatory pathways after immunization with GMZ2 malaria vaccine candidate in healthy lifelong malaria-exposed adults. Vaccine, 2020, 38, 4263-4272.	3.8	9
35	Unbiased metagenomic next-generation sequencing of blood from hospitalized febrile children in Gabon. Emerging Microbes and Infections, 2020, 9, 1242-1244.	6.5	8
36	Human Plasmodium vivax diversity, population structure and evolutionary origin. PLoS Neglected Tropical Diseases, 2020, 14, e0008072.	3.0	26

#	Article	IF	Citations
37	Burden of disease in Gabon caused by loiasis: a cross-sectional survey. Lancet Infectious Diseases, The, 2020, 20, 1339-1346.	9.1	30
38	Causes of fever in Gabonese children: a cross-sectional hospital-based study. Scientific Reports, 2020, 10, 2080.	3.3	7
39	Recombinase Polymerase Amplification and Lateral Flow Assay for Ultrasensitive Detection of Low-Density Plasmodium falciparum Infection from Controlled Human Malaria Infection Studies and Naturally Acquired Infections. Journal of Clinical Microbiology, 2020, 58, .	3.9	28
40	Characterization of Plasmodium infections among inhabitants of rural areas in Gabon. Scientific Reports, 2019, 9, 9784.	3.3	28
41	Controlled human malaria infection with Plasmodium falciparum demonstrates impact of naturally acquired immunity on virulence gene expression. PLoS Pathogens, 2019, 15, e1007906.	4.7	36
42	Novel reverse thia-analogs of fosmidomycin: Synthesis and antiplasmodial activity. European Journal of Medicinal Chemistry, 2019, 181, 111555.	5.5	6
43	Neutrophil extracellular traps drive inflammatory pathogenesis in malaria. Science Immunology, 2019, 4, .	11.9	108
44	DNA recovery from archived RDTs for genetic characterization of Plasmodium falciparum in a routine setting in LambarÃ©nÃ©, Gabon. Malaria Journal, 2019, 18, 336.	2.3	11
45	Experimental infections in humansâ€”historical and ethical reflections. Tropical Medicine and International Health, 2019, 24, 1384-1390.	2.3	11
46	First-in-human, Randomized, Double-blind Clinical Trial of Differentially Adjuvanted PAMVAC, A Vaccine Candidate to Prevent Pregnancy-associated Malaria. Clinical Infectious Diseases, 2019, 69, 1509-1516.	5.8	111
47	Transcriptome profiling reveals functional variation in Plasmodium falciparum parasites from controlled human malaria infection studies. EBioMedicine, 2019, 48, 442-452.	6.1	19
48	Ivermectin Impairs the Development of Sexual and Asexual Stages of Plasmodium falciparum In Vitro. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	21
49	Concentration and avidity of antibodies to different circumsporozoite epitopes correlate with RTS,S/AS01E malaria vaccine efficacy. Nature Communications, 2019, 10, 2174.	12.8	123
50	Prospective Clinical and Molecular Evaluation of Potential Plasmodium ovale curtisi and wallikeri Relapses in a High-transmission Setting. Clinical Infectious Diseases, 2019, 69, 2119-2126.	5.8	34
51	Human collectin-11 (COLEC11) and its synergic genetic interaction with MASP2 are associated with the pathophysiology of Chagas Disease. PLoS Neglected Tropical Diseases, 2019, 13, e0007324.	3.0	7
52	A retinal model of cerebral malaria. Scientific Reports, 2019, 9, 3470.	3.3	11
53	Monitoring of efficacy, tolerability and safety of artemetherâ€“lumefantrine and artesunateâ€“amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in LambarÃ©nÃ©, Gabon: an open-label clinical trial. Malaria Journal, 2019, 18, 424.	2.3	18
54	Schistosoma haematobium infection morbidity, praziquantel effectiveness and reinfection rate among children and young adults in Gabon. Parasites and Vectors, 2019, 12, 577.	2.5	18

#	Article	IF	Citations
55	Controlled Human Malaria Infection of Healthy Adults With Lifelong Malaria Exposure to Assess Safety, Immunogenicity, and Efficacy of the Asexual Blood Stage Malaria Vaccine Candidate GMZ2. Clinical Infectious Diseases, 2019, 69, 1377-1384.	5.8	53
56	8â€Aminoquinolines with an Aminoxyalkyl Side Chain Exert in vitro Dualâ€Stage Antiplasmodial Activity. ChemMedChem, 2019, 14, 501-511.	3.2	6
57	Nycteria and Polychromophilus parasite infections of bats in Central Gabon. Infection, Genetics and Evolution, 2019, 68, 30-34.	2.3	11
58	Clonal selection drives protective memory B cell responses in controlled human malaria infection. Science Immunology, 2018, 3, .	11.9	132
59	Prospective Clinical Trial Assessing Species-Specific Efficacy of Artemether-Lumefantrine for the Treatment of Plasmodium malariae, Plasmodium ovale, and Mixed Plasmodium Malaria in Gabon. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	17
60	Efficacy and Safety of Fosmidomycinâ€“Piperaquine as Nonartemisinin-Based Combination Therapy for Uncomplicated Falciparum Malaria: A Single-Arm, Age De-escalation Proof-of-Concept Study in Gabon. Clinical Infectious Diseases, 2018, 66, 1823-1830.	5.8	41
61	Rare PfCSP C-terminal antibodies induced by live sporozoite vaccination are ineffective against malaria infection. Journal of Experimental Medicine, 2018, 215, 63-75.	8.5	79
62	Baseline exposure, antibody subclass, and hepatitis B response differentially affect malaria protective immunity following RTS,S/AS01E vaccination in African children. BMC Medicine, 2018, 16, 197.	5.5	65
63	Behavioural and clinical predictors for Loiasis. Journal of Global Health, 2018, 8, 010413.	2.7	11
64	Correlating efficacy and immunogenicity in malaria vaccine trials. Seminars in Immunology, 2018, 39, 52-64.	5.6	23
65	Use of Capillary Blood Samples Leads to Higher Parasitemia Estimates and Higher Diagnostic Sensitivity of Microscopic and Molecular Diagnostics of Malaria Than Venous Blood Samples. Journal of Infectious Diseases, 2018, 218, 1296-1305.	4.0	13
66	Validity and reliability of methods to microscopically detect and quantify malaria parasitaemia. Tropical Medicine and International Health, 2018, 23, 980-991.	2.3	10
67	Antihomotypic affinity maturation improves human B cell responses against a repetitive epitope. Science, 2018, 360, 1358-1362.	12.6	89
68	Experimental infection of human volunteers. Lancet Infectious Diseases, The, 2018, 18, e312-e322.	9.1	120
69	Impact of Sickle Cell Trait and Naturally Acquired Immunity on Uncomplicated Malaria after Controlled Human Malaria Infection in Adults in Gabon. American Journal of Tropical Medicine and Hygiene, 2018, 98, 508-515.	1.4	60
70	Sterile protection against human malaria by chemoattenuated PfSPZ vaccine. Nature, 2017, 542, 445-449.	27.8	332
71	Distinct Helper T Cell Type 1 and 2 Responses Associated With Malaria Protection and Risk in RTS,S/AS01E Vaccinees. Clinical Infectious Diseases, 2017, 65, 746-755.	5.8	25
72	Bats are rare reservoirs of Staphylococcus aureus complex in Gabon. Infection, Genetics and Evolution, 2017, 47, 118-120.	2.3	19

#	Article	IF	Citations
73	Clinical development of a VAR2CSA-based placental malaria vaccine PAMVAC: Quantifying vaccine antigen-specific memory B & T cell activity in Beninese primigravidae. Vaccine, 2017, 35, 3474-3481.	3.8	16
74	DSM265 for Plasmodium falciparum chemoprophylaxis: a randomised, double blinded, phase 1 trial with controlled human malaria infection. Lancet Infectious Diseases, The, 2017, 17, 636-644.	9.1	83
75	Neutrophil alterations in pregnancyâ€associated malaria and induction of neutrophil chemotaxis by Plasmodium falciparum. Parasite Immunology, 2017, 39, e12433.	1.5	13
76	Design and Synthesis of Novel Antiâ€Plasmodial Histone Deacetylase Inhibitors Containing an Alkoxyamide Connecting Unit. Archiv Der Pharmazie, 2017, 350, 1600347.	4.1	9
77	The frontline of controlled human malaria infections: A report from the controlled human infection models Workshop in Leiden University Medical Centre 5 May 2016. Vaccine, 2017, 35, 7065-7069.	3.8	20
78	Natural Parasite Exposure Induces Protective Human Anti-Malarial Antibodies. Immunity, 2017, 47, 1197-1209.e10.	14.3	129
79	The GMZ2 malaria vaccine: from concept to efficacy in humans. Expert Review of Vaccines, 2017, 16, 907-917.	4.4	27
80	3-Hydroxy-Nâ€²-arylidenepropanehydrazonamides with Halo-Substituted Phenanthrene Scaffolds Cure P. berghei Infected Mice When Administered Perorally. Journal of Medicinal Chemistry, 2017, 60, 6036-6044.	6.4	4
81	Recognition of Plasmodium falciparum mature gametocyte-infected erythrocytes by antibodies of semi-immune adults and malaria-exposed children from Gabon. Malaria Journal, 2017, 16, 176.	2.3	11
82	Safety and efficacy of the choline analogue SAR97276 for malaria treatment: results of two phase 2, open-label, multicenter trials in African patients. Malaria Journal, 2017, 16, 188.	2.3	8
83	SAFETY OF RVSV EBOLA VACCINE, AFTER 6 MONTHS FOLLOW-UP, IN ADULTS: A PHASE 1 TRIAL CONDUCTED IN LAMBARÃ‰NÃ‰, GABON. BMJ Global Health, 2017, 2, A67.1-A67.	4.7	0
84	Safety and immunogenicity of rVSVÎ”G-ZEBOV-GP Ebola vaccine in adults and children in LambarÃ©nÃ©, Gabon: A phase I randomised trial. PLoS Medicine, 2017, 14, e1002402.	8.4	57
85	Life-span of in vitro differentiated Plasmodium falciparum gametocytes. Malaria Journal, 2017, 16, 330.	2.3	16
86	Species and genotype diversity of Plasmodium in malaria patients from Gabon analysed by next generation sequencing. Malaria Journal, 2017, 16, 398.	2.3	46
87	Intramuscular Artesunate for Severe Malaria in African Children: A Multicenter Randomized Controlled Trial. PLoS Medicine, 2016, 13, e1001938.	8.4	44
88	Mosquito Passage Dramatically Changes var Gene Expression in Controlled Human Plasmodium falciparum Infections. PLoS Pathogens, 2016, 12, e1005538.	4.7	54
89	Real-time measurement of Plasmodium falciparum-infected erythrocyte cytoadhesion with a quartz crystal microbalance. Malaria Journal, 2016, 15, 317.	2.3	5
90	A phase 2b randomized, controlled trial of the efficacy of the GMZ2 malaria vaccine in African children. Vaccine, 2016, 34, 4536-4542.	3.8	86

#	Article	IF	Citations
91	A single-dose antihelminthic treatment does not influence immunogenicity of a meningococcal and a cholera vaccine in Gabonese school children. Vaccine, 2016, 34, 5384-5390.	3.8	9
92	Sporozoite Route of Infection Influences In VitrovarGene Transcription ofPlasmodium falciparumParasites From Controlled Human Infections. Journal of Infectious Diseases, 2016, 214, 884-894.	4.0	17
93	Alterations of blood coagulation in controlled human malaria infection. Malaria Journal, 2016, 15, 15.	2.3	26
94	Associations Between Helminth Infections, Plasmodium falciparum Parasite Carriage and Antibody Responses to Sexual and Asexual Stage Malarial Antigens. American Journal of Tropical Medicine and Hygiene, 2016, 95, 394-400.	1.4	24
95	Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe. New England Journal of Medicine, 2016, 374, 1647-1660.	27.0	355
96	Natural infection of Plasmodium brasilianum in humans: Man and monkey share quartan malaria parasites in the Venezuelan Amazon. EBioMedicine, 2015, 2, 1186-1192.	6.1	115
97	Lessons from a modern review of the smallpox eradication files. Journal of the Royal Society of Medicine, 2015, 108, 473-477.	2.0	6
98	Controlled human malaria infection by intramuscular and direct venous inoculation of cryopreserved Plasmodium falciparum sporozoites in malaria-naÃ¯ve volunteers: effect of injection volume and dose on infectivity rates. Malaria Journal, 2015, 14, 306.	2.3	78
99	Prodrugs of Reverse Fosmidomycin Analogues. Journal of Medicinal Chemistry, 2015, 58, 2025-2035.	6.4	22
100	The effect of immunization schedule with the malaria vaccine candidate RTS,S/AS01E on protective efficacy and anti-circumsporozoite protein antibody avidity in African infants. Malaria Journal, 2015, 14, 72.	2.3	33
101	Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet, The, 2015, 386, 31-45.	13.7	1,127
102	Cytokine and chemokine profile of the innate and adaptive immune response of schistosoma haematobium and plasmodium falciparum single and co-infected school-aged children from an endemic area of LambarÃ©nÃ©, Gabon. Malaria Journal, 2015, 14, 94.	2.3	19
103	Direct venous inoculation of Plasmodium falciparum sporozoites for controlled human malaria infection: a dose-finding trial in two centres. Malaria Journal, 2015, 14, 117.	2.3	114
104	Workshop report: Malaria vaccine development in Europeâ€“preparing for the future. Vaccine, 2015, 33, 6137-6144.	3.8	15
105	Progress with Plasmodium falciparum sporozoite (PfSPZ)-based malaria vaccines. Vaccine, 2015, 33, 7452-7461.	3.8	152
106	Novel approaches to whole sporozoite vaccination against malaria. Vaccine, 2015, 33, 7462-7468.	3.8	48
107	Severe malaria in children leads to a significant impairment of transitory otoacoustic emissions - a prospective multicenter cohort study. BMC Medicine, 2015, 13, 125.	5.5	16
108	Fosmidomycin as an antimalarial drug: a meta-analysis of clinical trials. Future Microbiology, 2015, 10, 1375-1390.	2.0	37

#	Article	IF	Citations
109	Ferroquine and artesunate in African adults and children with Plasmodium falciparum malaria: a phase 2, multicentre, randomised, double-blind, dose-ranging, non-inferiority study. Lancet Infectious Diseases, The, 2015, 15, 1409-1419.	9.1	67
110	Effect of Antihelminthic Treatment on Vaccine Immunogenicity to a Seasonal Influenza Vaccine in Primary School Children in Gabon: A Randomized Placebo-Controlled Trial. PLoS Neglected Tropical Diseases, 2015, 9, e0003768.	3.0	21
111	The Influence of Sub-Unit Composition and Expression System on the Functional Antibody Response in the Development of a VAR2CSA Based Plasmodium falciparum Placental Malaria Vaccine. PLoS ONE, 2015, 10, e0135406.	2.5	42
112	Effect of Fluorescent Dyes on In Vitro -Differentiated, Late-Stage Plasmodium falciparum Gametocytes. Antimicrobial Agents and Chemotherapy, 2014, 58, 7398-7404.	3.2	15
113	High-throughput tri-colour flow cytometry technique to assess Plasmodium falciparum parasitaemia in bioassays. Malaria Journal, 2014, 13, 412.	2.3	18
114	Delayed Hemolysis After Treatment With Parenteral Artesunate in African Children With Severe Malariaâ€"A Double-center Prospective Study. Journal of Infectious Diseases, 2014, 209, 1921-1928.	4.0	77
115	Efficacy and Safety of the RTS,S/AS01 Malaria Vaccine during 18 Months after Vaccination: A Phase 3 Randomized, Controlled Trial in Children and Young Infants at 11 African Sites. PLoS Medicine, 2014, 11, e1001685.	8.4	367
116	In vitro growth of Plasmodium falciparum in neonatal blood. Malaria Journal, 2014, 13, 436.	2.3	7
117	Synthesis and study of cytotoxic activity of 1,2,4-trioxane- and egonol-derived hybrid molecules against Plasmodium falciparum andÂmultidrug-resistant human leukemia cells. European Journal of Medicinal Chemistry, 2014, 75, 403-412.	5.5	74
118	Binding Modes of Reverse Fosmidomycin Analogs toward the Antimalarial Target IspC. Journal of Medicinal Chemistry, 2014, 57, 8827-8838.	6.4	25
119	Antimalarial Activity of the Myxobacterial Macrolide Chlorotonil A. Antimicrobial Agents and Chemotherapy, 2014, 58, 6378-6384.	3.2	43
120	Limit of blank and limit of detection of Plasmodium falciparum thick blood smear microscopy in a routine setting in Central Africa. Malaria Journal, 2014, 13, 234.	2.3	48
121	Randomized, Controlled, Assessor-Blind Clinical Trial To Assess the Efficacy of Single- versus Repeated-Dose Albendazole To Treat Ascaris lumbricoides, Trichuris trichiura, and Hookworm Infection. Antimicrobial Agents and Chemotherapy, 2014, 58, 2535-2540.	3.2	57
122	Blood Schizontocidal and Gametocytocidal Activity of 3-Hydroxy-Nâ€²-arylidenepropanehydrazonamides: A New Class of Antiplasmodial Compounds. Journal of Medicinal Chemistry, 2014, 57, 7971-7976.	6.4	13
123	Loa loaâ€"does it deserve to be neglected?. Lancet Infectious Diseases, The, 2014, 14, 353-357.	9.1	72
124	Discovery of HDAC inhibitors with potent activity against multiple malaria parasite life cycle stages. European Journal of Medicinal Chemistry, 2014, 82, 204-213.	5.5	68
125	Humoral immune response to Plasmodium falciparum vaccine candidate GMZ2 and its components in populations naturally exposed to seasonal malaria in Ethiopia. Malaria Journal, 2013, 12, 51.	2.3	13
126	Atypical and classical memory B cells produce Plasmodium falciparum neutralizing antibodies. Journal of Experimental Medicine, 2013, 210, 389-399.	8.5	200

#	Article	IF	Citations
127	IspC as Target for Antiinfective Drug Discovery: Synthesis, Enantiomeric Separation, and Structural Biology of Fosmidomycin Thia Isosters. Journal of Medicinal Chemistry, 2013, 56, 8151-8162.	6.4	34
128	Novel approaches in antimalarial drug discovery. Expert Opinion on Drug Discovery, 2013, 8, 1325-1337.	5.0	15
129	Plasmodium vivax malaria in Duffy-negative individuals from Ethiopia. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2013, 107, 328-331.	1.8	63
130	The Malaria Vaccine Candidate GMZ2 Elicits Functional Antibodies in Individuals From Malaria Endemic and Non-Endemic Areas. Journal of Infectious Diseases, 2013, 208, 479-488.	4.0	60
131	Carriage of encapsulated bacteria in Gabonese children with sickle cell anaemia. Clinical Microbiology and Infection, 2013, 19, 235-241.	6.0	12
132	Broad-Spectrum Antimalarial Activity of Peptido Sulfonyl Fluorides, a New Class of Proteasome Inhibitors. Antimicrobial Agents and Chemotherapy, 2013, 57, 3576-3584.	3.2	24
133	2A and the Auxin-Based Degron System Facilitate Control of Protein Levels in Plasmodium falciparum. PLoS ONE, 2013, 8, e78661.	2.5	30
134	A Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Infants. New England Journal of Medicine, 2012, 367, 2284-2295.	27.0	653
135	In Vitro Activity of Fluorescent Dyes against Asexual Blood Stages of Plasmodium falciparum. Antimicrobial Agents and Chemotherapy, 2012, 56, 5982-5985.	3.2	17
136	Reduced antibody responses against Plasmodium falciparum vaccine candidate antigens in the presence of Trichuris trichiura. Vaccine, 2012, 30, 7621-7624.	3.8	48
137	A Simplified Intravenous Artesunate Regimen for Severe Malaria. Journal of Infectious Diseases, 2012, 205, 312-319.	4.0	38
138	Analysis of the Plasmodium falciparum proteasome using Blue Native PAGE and label-free quantitative mass spectrometry. Amino Acids, 2012, 43, 1119-1129.	2.7	20
139	Development and evaluation of a multiplex screening assay for Plasmodium falciparum exposure. Journal of Immunological Methods, 2012, 384, 62-70.	1.4	17
140	Emerging drugs for malaria. Expert Opinion on Emerging Drugs, 2012, 17, 319-333.	2.4	19
141	A flow cytometry-based workflow for detection and quantification of anti-plasmodial antibodies in vaccinated and naturally exposed individuals. Malaria Journal, 2012, 11, 367.	2.3	5
142	Prospective evaluation of artemether-lumefantrine for the treatment of non-falciparum and mixed-species malaria in Gabon. Malaria Journal, 2012, 11, 120.	2.3	34
143	Î±-Substituted Î²-Oxa Isosteres of Fosmidomycin: Synthesis and Biological Evaluation. Journal of Medicinal Chemistry, 2012, 55, 6566-6575.	6.4	31
144	Effect of IL-15 on IgG versus IgE antibody-secreting cells in vitro. Journal of Immunological Methods, 2012, 375, 7-13.	1.4	8

#	Article	IF	Citations
145	In vitro activity of new artemisinin derivatives against Plasmodium falciparum clinical isolates from Gabon. International Journal of Antimicrobial Agents, 2011, 37, 485-488.	2.5	8
146	First Results of Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Children. New England Journal of Medicine, 2011, 365, 1863-1875.	27.0	773
147	Threonine peptidases as drug targets against malaria. Expert Opinion on Therapeutic Targets, 2011, 15, 365-378.	3.4	17
148	A Randomized Controlled Phase Ib Trial of the Malaria Vaccine Candidate GMZ2 in African Children. PLoS ONE, 2011, 6, e22525.	2.5	70
149	Haematological and biochemical reference intervals for infants and children in Gabon. Tropical Medicine and International Health, 2011, 16, 343-348.	2.3	14
150	Schistosoma co-infection protects against brain pathology but does not prevent severe disease and death in a murine model of cerebral malaria. International Journal for Parasitology, 2011, 41, 21-31.	3.1	21
151	Assessment of LED fluorescence microscopy for the diagnosis of Plasmodium falciparum infections in Gabon. Malaria Journal, 2011, 10, 194.	2.3	20
152	Induction of Plasmodium falciparum-Specific CD4+ T Cells and Memory B Cells in Gabonese Children Vaccinated with RTS,S/AS01E and RTS,S/AS02D. PLoS ONE, 2011, 6, e18559.	2.5	41
153	New medicines for malaria. Wiener Klinische Wochenschrift, 2010, 122, 19-22.	1.9	2
154	Mitochondrial localization of the threonine peptidase PfHslV, a ClpQ ortholog in Plasmodium falciparum. International Journal for Parasitology, 2010, 40, 1517-1523.	3.1	24
155	Hemolysis Is Associated with Low Reticulocyte Production Index and Predicts Blood Transfusion in Severe Malarial Anemia. PLoS ONE, 2010, 5, e10038.	2.5	40
156	In Vitro Activity of Mirincamycin (U24729A) against Plasmodium falciparum Isolates from Gabon. Antimicrobial Agents and Chemotherapy, 2010, 54, 540-542.	3.2	23
157	In vitro activity of tigecycline in Plasmodium falciparum culture-adapted strains and clinical isolates from Gabon. International Journal of Antimicrobial Agents, 2010, 35, 587-589.	2.5	12
158	Safety and immunogenicity of the malaria vaccine candidate GMZ2 in malaria-exposed, adult individuals from LambarÃ©nÃ©, Gabon. Vaccine, 2010, 28, 6698-6703.	3.8	63
159	Reduced CD3/TCR complex expression leads to immunosuppression during Plasmodium falciparum malaria. Parasitology Research, 2009, 104, 575-582.	1.6	5
160	Immunological tests to diagnose active tuberculosis. Journal of Internal Medicine, 2009, 265, 159-162.	6.0	1
161	Safety and immunogenicity of GMZ2 â€" a MSP3â€"GLURP fusion protein malaria vaccine candidate. Vaccine, 2009, 27, 6862-6868.	3.8	98
162	In vitro activity of pyronaridine against Plasmodium falciparum and comparative evaluation of anti-malarial drug susceptibility assays. Malaria Journal, 2009, 8, 79.	2.3	37

#	Article	IF	Citations
163	Comprehensive study of proteasome inhibitors against Plasmodium falciparum laboratory strains and field isolates from Gabon. Malaria Journal, 2008, 7, 187.	2.3	94
164	Selection of a trioxaquine as an antimalarial drug candidate. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 17579-17584.	7.1	135
165	Fixedâ€Dose Pyronaridineâ€Artesunate Combination for Treatment of Uncomplicated Falciparum Malaria in Pediatric Patients in Gabon. Journal of Infectious Diseases, 2008, 198, 911-919.	4.0	91
166	New method to quantify erythrophagocytosis by autologous monocytes. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2007, 71A, 258-264.	1.5	12
167	Geschichte und Zukunft der Medizinischen Forschung am Albert Schweitzer Spital in LambarÃ©nÃ©, Gabun. Wiener Klinische Wochenschrift, 2007, 119, 8-12.	1.9	52
168	Parasites and pregnancy. Wiener Klinische Wochenschrift, 2007, 119, 681-684.	1.9	2
169	Plasmodia express two threonine-peptidase complexes during asexual development. Molecular and Biochemical Parasitology, 2006, 148, 79-85.	1.1	35
170	Malarial Parasites vs. Antimalarials: Never-Ending Rumble in the Jungle. Current Molecular Medicine, 2006, 6, 247-251.	1.3	22
171	Cord Blood Dendritic Cell Subsets in African Newborns Exposed to Plasmodium falciparum In Utero. Infection and Immunity, 2006, 74, 5725-5729.	2.2	29
172	Antimalarial Activity of a Synthetic Endoperoxide (RBx-11160/OZ277) against Plasmodium falciparum Isolates from Gabon. Antimicrobial Agents and Chemotherapy, 2006, 50, 1535-1537.	3.2	23
173	IN VITRO ACTIVITY OF FERROQUINE (SAR97193) IS INDEPENDENT OF CHLOROQUINE RESISTANCE IN PLASMODIUM FALCIPARUM. American Journal of Tropical Medicine and Hygiene, 2006, 75, 1178-1181.	1.4	49
174	In vitro activity of ferroquine (SAR97193) is independent of chloroquine resistance in Plasmodium falciparum. American Journal of Tropical Medicine and Hygiene, 2006, 75, 1178-81.	1.4	18
175	Increase in annexin V-positive B cells expressing LILRB1/ILT2/CD85j in malaria. European Cytokine Network, 2006, 17, 175-80.	2.0	14
176	Notch ligands Delta-like1, Delta-like4 and Jagged1 differentially regulate activation of peripheral T helper cells. European Journal of Immunology, 2005, 35, 2443-2451.	2.9	97
177	Clinical and Parasitological Characteristics of Puerperal Malaria. Journal of Infectious Diseases, 2005, 191, 1005-1009.	4.0	44
178	Artesunate-Clindamycin versus Quinine-Clindamycin in the Treatment ofPlasmodium falciparum Malaria: A Randomized Controlled Trial. Clinical Infectious Diseases, 2005, 40, 1777-1784.	5.8	64
179	Analysis of polymorphic sites in the promoter of the nitric oxide synthase 2 gene. Biochemical and Biophysical Research Communications, 2005, 335, 1123-1131.	2.1	13
180	The IÎºB Kinase Complex and NF-Îº B Actas Master Regulators of Lipopolysaccharide-Induced Gene Expressionand Control Subordinate Activation ofAP-1. Molecular and Cellular Biology, 2004, 24, 6488-6500.	2.3	152

#	Article	IF	Citations
181	Hemozoin (Malarial Pigment) Inhibits Differentiation and Maturation of Human Monocyte-Derived Dendritic Cells: A Peroxisome Proliferator-Activated Receptor-Î³-Mediated Effect. Journal of Immunology, 2004, 173, 4066-4074.	0.8	156
182	Characterisation of a Tryptophan-rich Plasmodium falciparum antigen associated with merozoites. Molecular and Biochemical Parasitology, 2004, 137, 349-353.	1.1	34
183	Lymphotoxin and lipopolysaccharide induce NFâ€ÎºBâ€p52 generation by a coâ€translational mechanism. EMBO Reports, 2003, 4, 82-87.	4.5	118
184	Nitric Oxide Synthase 2LambarÃ©nÃ©(Gâ€954C), Increased Nitric Oxide Production, and Protection against Malaria. Journal of Infectious Diseases, 2001, 184, 330-336.	4.0	152
185	Promoter Variants of the Human Mannose-Binding Lectin Gene Show Different Binding. Biochemical and Biophysical Research Communications, 2000, 275, 617-622.	2.1	31
186	Polymorphism in promoter region of inducible nitric oxide synthase gene and protection against malaria. Lancet, The, 1998, 351, 265-266.	13.7	165
187	Hyperparasitemia and Blood Exchange Transfusion for Treatment of Children with Falciparum Malaria. Clinical Infectious Diseases, 1998, 26, 850-852.	5.8	47
188	Antischistosome IgG4 and IgE Responses Are Affected Differentially by Chemotherapy in Children versus Adults. Journal of Infectious Diseases, 1996, 173, 1242-1247.	4.0	84
189	High efficacy of short-term quinine-antibiotic combinations for treating adult malaria patients in an area in which malaria is hyperendemic. Antimicrobial Agents and Chemotherapy, 1995, 39, 245-246.	3.2	35
190	Quinine plus clindamycin improves chemotherapy of severe malaria in children. Antimicrobial Agents and Chemotherapy, 1995, 39, 1603-1605.	3.2	75
191	Sulfadoxine/pyrimethamine or chloroquine/clindamycin treatment of Gabonese school children infected with chloroquine resistant malaria. Journal of Antimicrobial Chemotherapy, 1995, 36, 723-728.	3.0	25